Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619683 | 0.93 | ROCK1 (0.41) | RAB9AMEN1KMT2ANOTUMROCK2 | |
| SCHEMBL4773462 | 0.88 | LMNA (0.39) | RAB9AMEN1KMT2ANOTUMTAAR1 | |
| SCHEMBL4766432 | 0.86 | MEN1 (0.45) | RAB9AMEN1KMT2ANOTUMTAAR1 | |
| SCHEMBL14291275 | 0.83 | ALDH1A1 (0.42) | RAB9AMEN1KMT2ANOTUMTAAR1 | |
| SCHEMBL508668 | 0.82 | HPGD (0.42) | RAB9AMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL4770481 | 0.76 | KCNH2 (0.43) | MAPT | |
| SCHEMBL10254128 | 0.74 | P2RX7 (0.41) | L3MBTL1ALDH1A1MAPT | |
| SCHEMBL508731 | 0.74 | P2RX7 (0.41) | MAPT | |
| SCHEMBL13457968 | 0.73 | L3MBTL1 (0.39) | RAB9AMEN1KMT2ANOTUMTAAR1 | |
| SCHEMBL5225036 | 0.72 | LMNA (0.41) | MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556381-B1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | PFIZER LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1556381-B1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | PFIZER LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1556381-A1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | Pfizer Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20050004129-A1 | Pyrazole derivatives | PFIZER, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004029051-A1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | PFIZER LIMITED (GB) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004129-A1 | Pyrazole derivatives | RTF1, RRM2B, RRM2 | RAB9A 2118/4885MEN1 4755/4885KMT2A 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.